Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

58364 1487845784HCLSReviewSingaporeFeb2017.pdf
Energy Boardroom

Boehringer Ingelheim, Eli Lilly can resubmit NDA for diabetes drug with warning letter resolved

03.06.2014 / Fierce Pharma

Boehringer Ingelheim has finally received some good news for its manufacturing facility in Ingelheim, Germany. The FDA has notified it that it has closed out a warning letter for the facility.

Cover_HCLS_Singapore LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: